Tag: CanChew

March 7, 2017

Medical Marijuana Investment AXIM® Biotech Announces Enrolled Patients Begin Phase II Trial For The Treatment Of Irritable Bowel Syndrome

Medical Marijuana, Inc. (OTC:MJNA) major investment company AXIM® Biotechnologies announced the enrolment of 40 patients and started its Phase II clinical trial for...
January 18, 2017

AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum

AXIM® Biotechnologies (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome...
January 4, 2017

CBD Market Estimated to Grow to $2.1B by 2020, Report Finds

A recent report by Forbes.com highlights the tremendous growth expceted in the cannabidiol (CBD) market over the next three years....
January 4, 2017

AXIM® Biotech Receives Positive PK Data Results for CanChew Plus® CBD Gum

AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK) data results...
December 6, 2016

AXIM® Biotech Receives Medical Ethical Committee Approval to Begin IBS Trial for Canchew Plus® CBDGum

AXIM® Biotechnologies today announced that it received approval from the Medical Ethical Committee of Wageningen University, The Netherlands, to begin...
November 1, 2016

AXIM Biotech Begins PK/PD Studies With CanChew Plus CBD Gum for IBS Symptoms

AXIM® Biotechnologies, a world leader in cannabinoid research and development, today announced that it has begun pharmacokinetic/pharmacodynamics studies with its...
September 19, 2016

AXIM® Biotech Signs Exclusive Distribution Agreement With Israel’s Rafa Pharmaceuticals

AXIM® Biotechnologies, Inc. (OTC:AXIM), an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products,...